Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 26, 2026.

The role of short-chain fatty acids in inflammatory skin diseases

Xianjun Xiao, Xiaoshen Hu, Junpeng Yao and 11 more

Frontiers in Microbiology · 2023 · Review · CC BY

doi:10.3389/fmicb.2022.1083432

Abstract

Short-chain fatty acids (SCFAs) are metabolites of gut microbes that can modulate the host inflammatory response, and contribute to health and homeostasis. Since the introduction of the gut-skin axis concept, the link between SCFAs and inflammatory skin diseases has attracted considerable attention. In this review, we have summarized the literature on the role of SCFAs in skin inflammation, and the correlation between SCFAs and inflammatory skin diseases, especially atopic dermatitis, urticaria, and psoriasis. Studies show that SCFAs are signaling factors in the gut-skin axis and can alleviate skin inflammation. The information presented in this review provides new insights into the molecular mechanisms driving gut-skin axis regulation, along with possible pathways that can be targeted for the treatment and prevention of inflammatory skin diseases.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 26, 2026. Paragraph numbers are ours, so an answer can point at one.

1. Introduction

Inflammatory skin disease refers to the inflammation response in the skin, which manifests as skin redness, swelling, itching or scaling. Common inflammatory skin diseases, including atopic dermatitis (AD), psoriasis, acne, and urticaria, are associated with other comorbidities and impose a significant burden on the patients. Although the above diseases vary in their clinical presentation, they may share common physio-pathological pathways. Recent studies have shown that the gut microbiome is an important factor influencing host immunity, inflammation and metabolism. The gut-skin axis is a fairly recent concept that refers to the bidirectional relationship between the gut microbiome and skin, and an increasing body of evidence suggests that changes in the gut microbiome is related with skin inflammation. The gut and the skin are both highly innervated and vascularized organs, and harbor numerous resident microorganisms with similar functions. Furthermore, various skin conditions have been linked to an altered gut microbiome.

Short-chain fatty acids (SCFAs), mainly including acetate, propionate, butyrate, isobutyrate, valerate, and isovalerate, contain less than 6 carbon atoms and are the final product of the fermentation of resistant starch and dietary fiber by specific gut microbiota. SCFAs are transported from the intestine to distant organs and tissues through the peripheral circulation, and bind to G protein-coupled receptors (GPCRs) that are expressed on skin cells, leukocytes, neutrophils, and other types of cells, thereby exerting direct influence on tissue metabolism and function. Recent studies have shown that SCFAs mitigate inflammation by regulating the production of cytokines by immune cells such as neutrophils, macrophages, dendritic cells (DCs) and T-cells. However, the role of SCFAs in inflammatory skin diseases has not been completely elucidated. In this review, we summarized the literature on the relationship between SCFAs and skin inflammation, and discussed the therapeutic potential of SCFAs against inflammatory skin diseases.

2. The potential pathway of SCFAs in inflammatory skin diseases

The potential anti-inflammatory mechanisms of SCFAs in inflammatory skin diseases are related to specific membrane receptors, histone deacetylase (HDAC) inhibitors, and metabolic pathways (Figure 1).

2.1. SCFA receptors pathway

Short-chain fatty acid receptors are activated upon binding to the ligand and facilitate SCFAs entry into cells. The established SCFAs receptors include G protein-coupled receptor 41 (GPR41) [a.k.a free fatty acid receptor 3 (FFAR3)], G protein-coupled receptor 43 (GPR43) [a.k.a. free fatty acid receptor 2 (FFAR2)], G protein-coupled receptor 109A (GPR109A) [a.k.a. hydroxycarboxylic acid receptor 2 (HCA2)], Olfr-78 (for murine), OR51E2 (for human), aryl-hydrocarbon receptor (AHR) and peroxisome proliferator-activated receptors γ (PPARγ). SCFA-mediated receptors play an important role in regulating the inflammatory response of the host. FFAR2-deficient mice exhibit exacerbated inflammation in mouse models of arthritis, colitis, and asthma, and similar dysregulation in germ-free mice with low or no SCFA expression. These results show that SCFAs interact with GPR43 profoundly affect the inflammatory response. SCFAs act via FFAR2/3 to attenuate the secretion of various inflammatory cytokine and modulate the inflammatory response of human monocytes. Moreover, SCFAs activate GPR43 and GPR109a to regulate inflammatory response of the host by downregulation of NF-κB signaling pathway. Additionally, the PPARγ not only competitively inhibits the activation of NF-κB, but also cooperates with SCFAs to suppress the phosphorylation of NF-κB signaling pathway.

Recent studies have shown that SCFA receptors are closely related to the pathogenesis of inflammatory skin diseases. AHR expression significantly increase in the serum and skin lesions of patients with AD, whereas PPARγ, GPR43, and GPR109a downregulate in psoriasis. Moreover, a study has indicated that butyrate can increase the expression of GPR43 and GPR109a in psoriasis and exert anti-inflammatory effects. The binding of these receptors to SCFAs activates intracellular signaling pathways that regulate cellular responses, immune function, and inflammation.

Taken together, alterations in the expression of SCFAs-mediated receptors may involve in the pathogenesis of inflammatory skin diseases. Existing evidence suggests that SCFAs may play an anti-inflammatory role in inflammatory skin diseases by restoring the expression of SCFAs-mediated receptors, but the specific mechanism is rarely reported. Future studies are needed to gain insight into the anti-inflammatory role of SCFAs in inflammatory skin diseases.

2.2. HDAC inhibition and associated pathway

The dynamic balance between histone acetylases (HATs) and HDACs controls chromatin structure and gene expression. HDAC inhibitors deacetylate histones in the promoter regions, resulting in the transcriptional activation of the downstream genes. The anti-inflammatory effects of SCFAs have been attributed to their ability to inhibit HDAC activity. For instance, SCFA blocks CXCL10 release through HDAC inhibition, reduce inflammation and maintain immune homeostasis and gut health. Furthermore, butyrate promotes FOXP3 expression in naive CD4+ T-cells and induces their differentiation into peripheral-derived Tregs (pTregs) by inhibiting HDACs, while acetate, propionate and butyrate can modulate the immune response of DCs, macrophages and Treg cells by inhibiting HDACs. Imiquimod (IMQ)-induced psoriasis-like skin inflammation model reduces the suppressive activity of Treg, and then upregulates IL-17 and IL-6, and downregulates IL-10 and FOXP3, whereas butyrate can reverse these progressions by inhibiting HDACs (Figure 1). In LPS-activated neutrophils, application of both butyrate and propionate inhibits NF-κB activity and reduces TNF-α production mainly by inhibiting HDACs. In addition, SCFAs can alleviate systemic inflammation by significantly reducing the production of TNF-α and IL-6 through the downregulation of HDACs mRNAs. Propionibacterium acnes in the skin activate toll-like receptor-2 (TLR-2) and promote the secretion of inflammatory factors such as IL-6, IL-8, and TNF-α, thereby inducing skin inflammation. This process may be attenuated by SCFAs via inhibiting HDACs. Furthermore, Butyrate enhances the expression of filaggrin (FLG) and transglutaminase-1 (TGM1) and promotes normal human epidermal keratinocytes (NHEKs) terminal differentiation to maintain skin homeostasis by inhibiting HDACs (Figure 1).

Overall, SCFAs can reduce the release of inflammatory cytokines and promote the differentiation of epidermal keratinocytes via inhibiting HDACs, thereby playing an anti-inflammatory role in inflammatory skin diseases.

2.3. Metabolic pathway

Short-chain fatty acids can affect cellular metabolism by promoting mitochondrial fatty acid β-oxidation (FAO). Skin barrier dysfunction is a common pathological feature of inflammatory skin diseases. Recent studies have shown that SCFAs is able to improve the skin barrier and relieve skin inflammation by altering mitochondrial metabolism and function. Butyrate is metabolized by epidermal keratinocytes, which in turn enhances the synthesis of keratinocyte-derived long-chain fatty acids (LCFAs) and very long-chain fatty acids (VLCFAs), a key event in the subsequent generation of ceramides that are critical to skin barrier function. Interestingly, this phenomenon is limited to the skin, since butyrate has little effect on systemic LCFA and VLCFA levels. Furthermore, butyrate can also enhance LCFA uptake (Figure 1). Genetic variation in the mitochondrial genome is associated with chronic inflammatory skin disease. Intriguingly, in mice with antibody-induced dermatitis, propionate-treated disease progression pattern is similar to that of mitochondrial gene variant (B6-mtFVB) mice, both effectively reducing the severity of inflammatory skin disease.

Thus, the anti-inflammatory effects of butyrate on the skin can be attributed to fueling FAO (directly and indirectly) and altering mitochondrial metabolism, promoting keratinocyte differentiation, and improving the skin barrier.

3. Relationship between SCFAs and inflammatory skin diseases

Many studies have reported the interaction between SCFAs and inflammatory skin diseases. We reviewed the effects of SCFAs on AD, eczema, acne, chronic spontaneous urticaria (CSU), and psoriasis.

3.1. SCFAs in atopic dermatitis

Atopic dermatitis is a chronic inflammatory skin disease that is caused by a number of genetic, environmental, and immunological factors. Recent studies show that the symptoms of AD are the result of a systemic immune response induced by changes in the gut microecology. Furthermore, evidence demonstrates that the intestinal levels of SCFAs correlate with the onset of AD. For instance, Patients with AD have low levels of fecal SCFAs, which corresponds to a significant reduction in the abundance of SCFA-producing bacteria. Similar trends have been observed in animal models as well. Moreover, the severity of AD correlates negatively with the abundance of butyrate-producing bacteria. A follow-up study of children aged 6–24 months revealed lower levels of butyrate and valerate in infants with transient AD compared to the healthy infants and those with persistent AD. Other studies have shown that infants younger than 3 years with AD have lower amounts of propionate and butyrate in their first year. Similar patterns have been observed in mixed age groups (see Table 1). Consistent with the above findings, mice exhibiting AD-like symptoms induced with transdermal injection of 2,4-dinitrochlorobenzene have lower SCFA levels compared to the healthy littermates. Furthermore, the symptoms of AD in these mice are relieved after treatment, and the SCFA levels are normalized. These findings underscore the role of the SCFAs as signaling molecules of the gut-skin axis.

The development of AD is closely related to immune dysregulation, microbial exposure, disrupted skin barrier and intestinal dysbiosis. An imbalance between the pro-inflammatory CD4+IL17+ T-cells and the anti-inflammatory CD4+FOXP3+ regulatory T-cells (Tregs) in the gut may be a key determinant of early AD development. Both propionate and butyrate contribute to the accumulation of Tregs in the colon through activation of DCs and T-cells or G protein signaling. Therefore, restoring the balance between the intestinal T-cell subpopulations by SCFAs supplementation may mitigate the symptoms of AD. Low levels of SCFAs may also increase intestinal permeability and disrupt its barrier function, eventually triggering AD. SCFAs are partly absorbed by the intestine and the remainder enter the bloodstream, and are distributed to various organs and tissues. Therefore, SCFAs may act directly on skin cells to regulate the barrier function. Keratinocytes exposed to TNF-α and IFN-γ express aberrantly high levels of the pro-inflammatory cytokine IL-6, and the intercellular adhesion molecule-1 (ICAM-1), which in turn recruit monocytes to the epidermis. These inflammatory keratinocytes involve in the pathophysiology of AD. SFCAs markedly reduce IL-6 and ICAM-1 mRNA levels in human keratinocytes (HaCaT cells) stimulated with TNF-α and INF-γ in vitro (Figure 1). In addition, butyrate also inhibits the inflammatory phenotype of cultured human keratinocytes by inducing acetylation of histone H3 lysine 9 (AcH3K9).

The pathogenesis of AD is also related to an imbalance in the skin microecology. The skin of AD patients is more susceptible to the colonization and overgrowth of pathogenic bacteria due to the lower abundance of probiotic bacteria, which inhibit the growth of pathogens through metabolites. For instance, the SCFAs produced during fermentation by beneficial bacteria have an inhibitory effect on community-associated methicillin-resistant Staphylococcus aureus. S. aureus is abundant in the AD skin, and promotes inflammation by binding to and activating TLR-2, resulting in IL-4-mediated inhibition of IL-10. SCFAs not only improve the local skin microflora but also restrain the migration of immune cells and the production of TNF-α, IL-6, and IL-8 (Figure 1).

In summary, SCFAs are closely related to the pathogenesis of AD. The level of SCFAs in AD patients is generally lower than that in healthy controls. Low levels of fecal SCFAs may increase intestinal permeability and induce AD. However, transcutaneously induced AD-like animal models can also reduce intestinal SCFAs levels, but little is known about SCFAs expression in lesion skin. In future studies, it is recommended to add the measurement of SCFAs expression in AD-damaged skin to better illustrate the role of SCFAs in inflammatory skin diseases.

3.2. SCFAs in eczema

Eczema is a common inflammatory skin disease with underlying genetic and environmental causes. Studies show that gut microecology is an important environmental factor in the occurrence of eczema, and SCFA levels can predict the risk of eczema. The decrease in SCFA level precedes eczema symptoms. Lower levels of fecal butyrate and valerate have been observed in 6-month-old infants with eczema, and butyrate levels, in particular, have negative correlation with the development of eczema. This is consistent with the inverse correlation between low microbial complexity in early infancy and the likelihood of allergies in later life. Furthermore, most patients with eczema have low levels of SCFAs, and low fecal valerate levels in childhood is related to a higher incidence of eczema in youth. These findings indicate that low levels of SCFAs may increase the susceptibility to eczema. However, research concerning the role of SCFAs in the pathogenesis of eczema is mainly focused on infants and young children, and it is unclear whether these findings can be extrapolated to adult patients as well. More clinical evidence is needed to elucidate the correlation between SCFAs and eczema.

Interleukin-17 (IL-17) is expressed in different subtypes of eczema and can enhance the inflammatory symptoms. Valerate can inhibit IL-17 release by promoting IL-10 production via the CD4+ T-cells and regulatory B-cells, a process which involves reprogramming lymphocyte metabolism and inhibition of HDAC activity. Butyrate can also diffuse through the intestinal epithelial cells, promote the differentiation of naive T-cells to Tregs, and prevent allergic diseases such as eczema. Furthermore, the development of eczema is often associated with impaired skin barrier function. Keratin (KRT1) and FLG play a crucial role in the maintenance of a healthy skin barrier. KRT1-deficient mice have a compromised skin barrier, and their skin transcriptome resembles that of eczema skin. Valerate can improve skin tissue integrity and barrier function by upregulating KRT1 and tight junction proteins. Recent studies reveal that the etiology of eczema is closely related to the genetic loss of FLG, which leads to dryness and impaired skin barrier function. Butyrate and propionate can increase the expression of FLG protein by inhibiting the activity of HDAC, and restoring the function and permeability of the epidermal barrier.

Taken together, low levels of SCFAs may increase susceptibility to eczema. SCFAs are capable of improving the skin barrier and alleviating the skin inflammation of eczema. However, the clinical application of SCFA in eczema needs further investigation.

3.3. SCFAs in acne

Acne is a common inflammatory skin condition caused by the overgrowth of P. acnes. The probiotic Staphylococcus epidermidis can inhibit bacterial colonization and P. acnes-induced inflammation at the lesions by producing SCFAs. Propionate and butyrate are ligands of GPR41, which are upregulated through the SCFAs produced by S. epidermidis. In addition, the latter may alleviate P. acnes-induced inflammation by inhibiting HDAC activity. The protective function of SCFAs depends on the routes of administration. Subcutaneous injection of SCFAs and P. acnes in mice abrogated the upregulation of inflammatory genes, as opposed to topical application of the SCFAs on the back. These results indicate that SCFAs can inhibit the growth of P. acnes, and their anti-inflammatory effects depend on the mode of application. The exact mechanisms underlying the differential effects of SCFAs on the epidermal and subcutaneous tissues are unclear. The same SCFAs may exert different effects in different application environments. How to apply SCFAs safely and effectively against skin inflammation (the dose of SCFAs, the site, and the application environment, etc.) become research highlights.

3.4. SCFAs in chronic spontaneous urticaria

Chronic spontaneous urticaria is a type of chronic inflammatory dermatosis that is predominantly mast cell-driven. Alterations in gut metabolites may exacerbate the inflammatory response and immune dysfunction during the pathogenesis of CSU. In addition, reduced SCFAs accumulation due to an imbalance in the intestinal flora may play an important role in the pathogenesis of CSU. Clinical studies have shown that the levels of fecal isobutyrate and serum butyrate are lower in CSU patients compared to that in healthy individuals. This is consistent with the observation that butyrate represses mast cell proliferation, degranulation and cytokine production in mice, and reduces the levels of inflammatory cytokines. SCFAs bind to receptors (such as GPR43 and PPARγ) that are expressed on mast cells, and inhibit the inflammatory response, mast cell maturation, and even dermatitis. Thus, SCFA-specific receptors expressed on mast cells are potential therapeutic targets for CSU. A recent study demonstrates that SCFAs suppress the activity of human and murine primary mast cells by inhibiting HDAC independent of GPR41, GPR43, and nuclear PPAR receptors. This suggests that SCFAs inhibit mast cell activation and inflammatory responses through multiple pathways. In addition, SCFAs can inhibit mast cell activation in vitro and in vivo at levels comparable to that in the intestine and serum of human, without affecting cell viability. Therefore, it may be a promising direction to study the pathogenesis and treatment of CSU based on SCFAs.

3.5. SCFAs in psoriasis

Psoriasis is an immune-mediated inflammatory skin disease with complex pathogenesis. It manifests as chronic inflammation and subsequent epidermal hyperplasia, resulting in silvery scales and thickening of the skin. Altered intestinal microecology is a pathological factor in psoriatic development. One study discovers that serum acetate and propionate levels are lower in patients with psoriasis compared to healthy individuals. Furthermore, serum acetate and propionate levels correlate negatively with that of IL-23/IL-27 in an IMQ-induced mouse model of psoriasis, and administration of these SCFAs alleviates the inflammatory symptoms. Psoriatic progression depends on the activation of the TNF-α/IL-23/IL-17 signaling axis, and the hyperproliferation and aberrant differentiation of epidermal keratinocytes. IL-23 induces the transformation of Tregs to the T helper type 17 (Th17) cells, whereas IL-17A reduces transforming growth factor (TGF)-β1 production and Foxp3 expression, and inhibits Treg activity. Decreased Treg activity in patients with psoriasis is closely related to the level of SCFAs, and the beneficial effects of SCFAs are also dependent on the role of Tregs. In addition, the genes involved in SCFA metabolism are significantly downregulated in patients with psoriasis, which may be associated with Treg dysfunction. Administration of SCFAs can improve the symptoms of psoriasis by inhibiting HDACs in the Tregs and restoring their activity. Furthermore, SCFAs can promote the expansion of peripherally derived Tregs, although there is a lack of psoriasis-targeted studies.

G protein-coupled receptor 109A and GPR43 are expressed at significantly lower levels in the keratinocytes of psoriasis patients compared to that of healthy individuals, and topical application of butyrate can restore their expression levels. In addition, in vitro experiments have shown that butyrate can upregulate filaggrin and TGM1 transcripts in cultured human keratinocytes and promote the formation of cornified envelope, which may help improve psoriatic lesions. In fact, topical application of SCFAs reduce both IMQ-induced psoriasis and systemic inflammatory responses in mice. Hence, these studies suggest that SCFAs may be involved in the regulation of psoriasis by restoring Treg activity and promoting the formation of cornified envelope.

4. SCFA-based therapy for inflammatory skin diseases

In recent years, SCFAs have emerged in the field of inflammatory skin diseases as an anti-inflammatory modulator, but it is still in its infancy. Therefore, understanding the application of SCFAs in the treatment of inflammatory skin diseases can pave a path for future clinical practice.

4.1. Topical administration of SCFAs in inflammatory skin diseases

The skin is the first line of defense against biological, physical, and chemical stresses. Numerous viruses, bacteria, archaea, fungi, and mites reside on the skin surface which constitute the skin microbiome. Skin-resident microbes maintain cutaneous homeostasis and regulate the local inflammatory response, and any disruption in the skin microbiome can induce an inflammatory reaction. Local application of SCFAs can promote the growth of beneficial microbes, and topical administration of probiotics promotes the release of SCFAs to mitigate skin inflammation. In a trial to validate acetate for AD, topical application of apple cider vinegar (0.5% acetate) for 2 weeks did not affect the skin microbiome of healthy subjects and AD patients compared to the water placebo group, and also did not prevent the colonization of S. aureus on the inflamed skin. However, no significant difference was observed in the diversity of the skin microbiome between the AD patients and healthy subjects at baseline. Therefore, the inhibitory effect of apple cider vinegar on S. aureus growth may depend on the bacterial strain and the levels of acetate. On the other hand, in mice with IMQ-induced skin inflammation, topical injection of acetate led to further exacerbation of skin inflammation. Similarly, topically (2% w/w) and systemically administered (200 mmol/L) acetate was used to enhance psoriasis-like signs in an animal model of IMQ-induced psoriasis. Therefore, the net effects of the actions of SCFAs are context-dependent and can be pro- or anti-inflammatory. The exact effects of SCFAs may depend on the type of SCFAs, the delivery method, the levels and the health condition of hosts. Moreover, fermentation initiators such as sucrose can selectively promote SCFA production by the probiotic S. epidermidis, and improve acne dysbiosis. Topical application of butyrate not only inhibits allergic contact inflammation in a mouse model, but also alleviates skin inflammation and the expression of inflammatory factors related to psoriasis.

However, most SCFAs have an offensive odor and are therapeutically effective only at certain concentrations, which significantly limit their clinical use. SCFA derivatives can obviate these limitations. The butyrate derivative BA-NH-NH-BA consists of two butyrate molecules with a -NH-O-NH- linker. It inhibits HDAC activity at a lower level compared to butyrate, and mitigates S. aureus growth and the inflammatory response in a mouse model. Taken together, the topical application of SCFAs have broad effects on the skin microbiome, skin barrier, and related inflammatory factors.

4.2. Oral supplementation of SCFAs in inflammatory skin diseases

Gut microbes have the ability to modulate systemic inflammation, and imbalances in the gut microbes can manifest as inflammatory skin diseases. The beneficial effects of the gut microbiota on host health are closely associated with SCFAs. Given the similarities in the gut and skin microbiomes, orally administered SCFAs can potentially exert an anti-inflammatory effect on the skin as well.

Probiotics are living microorganisms that have beneficial effects on host health, and can maintain intestinal homeostasis by restoring SCFA levels. Studies increasingly show that skin inflammation is closely related to SCFA production. Oral administration of Bifidobacterium adolescentis in mice with DNFB-induced AD significantly improves AD-like symptoms, such as skin damage and swelling, which correlates with increased levels of propionate and butyrate and decreased levels of isovalerate. Regular cheese consumption also introduces probiotics into the gastrointestinal tract and increases the production of SCFAs. In one study, the neuroprotective effects of Lactococcus chungangensis CAU 28-fermented cream cheese and L. chungangensis CAU 28 dry cells are compared in a mouse model of AD. The CAU 28 cream cheese results in better outcomes, which can be attributed to a more abundant supply of SCFAs compared to the bacterial cells. Furthermore, oral administration of CAU 28 cream cheese induces a coordinated immune response involving SCFAs and gut microbiota, and effectively improves symptoms of AD. Oral supplementation with multistrain probiotics (IRT5) can be the alternative therapeutics for the prevention and treatment of skin allergies. Its mechanism of action is mainly attributed to IRT5-induced propionate which is the key immunomodulatory metabolite for the Treg cells expansion and relieving skin inflammation. Moreover, A study has showed that sialyllactose and galactooligosaccharides are capable to promote re-epithelialization and repair epidermal wound, which is related to differential changes in SCFA profiles.

Glycomacropeptides (GMPs) are bioactive peptides extracted from dietary proteins that are beneficial to human health. Prophylactic feeding of glycopeptides induces SCFA production, and prevents and reverses AD-like skin lesions in rats. Studies show that the protective effect of GMPs on the skin barrier may be mediated by the direct effects of acetate and butyrate on local skin cells. Taken together, oral administration of SCFAs can alleviate the symptoms of inflammatory skin diseases. More clinical studies are needed to confirm the effectiveness of oral supplementation of SCFAs.

5. Conclusion

The skin anti-inflammatory effects of SCFAs have been studied in rodents experimental models, but the implication of these findings to the human population is still debatable. Restoring the production of SCFAs may relieve the symptoms of skin inflammation by directly inhibiting the inflammatory factors, improving immune homeostasis, and preventing colonization by pathogenic bacteria. Nevertheless, the mechanism of SCFAs toxicities remains largely unknown.

The current understanding of SCFAs-associated anti-inflammatory effects in inflammatory skin diseases is still limited and is a nascent area of research that requires further investigation. Targeted metabolomics of lesioned skin specimens in patients with inflammatory dermatoses may provide new insights into the molecular basis of their action. Several studies focus on the predominant SCFAs including acetate, propionate, and butyrate. Nevertheless, little is known regarding the effects of other SCFAs, which may play a key anti-inflammatory role. Future studies on valerate and isobutyrate may bring new perspectives on the effects of SCFAs on inflammatory skin diseases. Given the unpleasant taste of SCFAs, it is necessary to develop derivatives that are functionally similar and can be incorporated into clinical application. However, the long-term safety and efficacy of SCFA derivatives warrant further investigation. Encouraging evidence supports the effect of SCFAs in the treatment of AD, psoriasis, acne, and urticaria and SCFAs have therapeutic potential against chronic wounds, alopecia, and seborrheic dermatitis as well. Given the close correlation between SCFA expression and skin inflammation occurrence, SCFAs could be used to detect the therapeutic efficacy and to predict the prognosis of inflammatory skin diseases. A deeper understanding of SCFAs in inflammatory skin diseases provides a systematic theoretical basis for studying SCFAs as potential drugs for promoting human skin health.

Author contributions

XX, XH, and JY: conceptualization and supervision. WC, ZZ, LW, HQ, DZ, and PX: resources. XX, XH, JY, ZZ, YXL, and LW: literature review and writing – original draft preparation. XX, XH, RJ, YL, YS, and JL: writing – review and editing. All authors have read and agreed to the published version of the manuscript.

References 139

  1. 1.

    Aguilar E. C. Silva J. F. D. Navia-Pelaez J. M. Leonel A. J. Lopes L. G. Menezes-Garcia Z. (2018 ). Sodium butyrate modulates adipocyte expansion, adipogenesis, and insulin receptor signaling by upregulation of PPAR-γ in obese apo E knockout mice. Nutrition 47 75–82.

    Not in our library10.1016/j.nut.2017.10.007

  2. 2.

    Ahn R. Gupta R. Lai K. Chopra N. Arron S. T. Liao W. (2016 ). Network analysis of psoriasis reveals biological pathways and roles for coding and long non-coding RNAs. BMC Genomics 17:841.

    Not in our library10.1186/s12864-016-3188-y

  3. 3.

    Ang Z. Er J. Z. Tan N. S. Lu J. Liou Y.-C. Grosse J. (2016 ). Human and mouse monocytes display distinct signalling and cytokine profiles upon stimulation with FFAR2/FFAR3 short-chain fatty acid receptor agonists. Sci. Rep. 6:34145.

    Not in our library10.1038/srep34145

  4. 4.

    Aoyama M. Kotani J. Usami M. (2010 ). Butyrate and propionate induced activated or non-activated neutrophil apoptosis via HDAC inhibitor activity but without activating GPR-41/GPR-43 pathways. Nutrition 26 653–661.

    Not in our library10.1016/j.nut.2009.07.006

  5. 5.

    Arpaia N. Campbell C. Fan X. Dikiy S. Veeken J. V. D. deRoos P. (2013 ). Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504 451–455.

    Not in our library10.1038/nature12726

  6. 6.

    Artym J. Zimecki M. (2013 ). Milk-derived proteins and peptides in clinical trials. Postepy Hig. Med. Dosw. 67 800–816.

    Not in our library10.5604/17322693.1061635

  7. 7.

    Bachem A. Makhlouf C. Binger K. J. Souza D. P. D. Tull D. Hochheiser K. (2019 ). Microbiota-derived short-chain fatty acids promote the memory potential of antigen-activated CD8(+) T cells. Immunity 51 285–297.

    Not in our library10.1016/j.immuni.2019.06.002

  8. 8.

    Batta M. G. Spetz K. Barman M. Bråbäck L. Norin E. Björkstén B. (2021 ). Low concentration of fecal valeric acid at 1 year of age is linked with eczema and food allergy at 13 years of age: Findings from a Swedish birth cohort. Int. Arch. Allergy Immunol. 138 398–408.

    Not in our library10.1159/000520149

  9. 9.

    Benedetto A. D. Rafaels N. M. McGirt L. Y. Ivanov A. I. Georas S. N. Cheadle C. (2011 ). Tight junction defects in patients with atopic dermatitis. J. Allergy Clin. Immunol. 127 773–786.

    Not in our library10.1016/j.jaci.2010.10.018

  10. 10.

    Beránek M. Fiala Z. Kremláček J. Andrýs C. Krejsek J. Hamáková K. (2018 ). Serum levels of aryl hydrocarbon receptor, cytochromes P450 1A1 and 1B1 in patients with exacerbated psoriasis vulgaris. Folia Biol. 64 97–102.

    Not in our library10.14712/fb2018064030097

  11. 11.

    Bisgaard H. Li N. Bonnelykke K. Chawes B. L. K. Skov T. Paludan-Müller G. (2011 ). Reduced diversity of the intestinal microbiota during infancy is associated with increased risk of allergic disease at school age. J. Allergy Clin. Immunol. 128 646–652.e1-5.

    Not in our library10.1016/j.jaci.2011.04.060

  12. 12.

    Boets E. Gomand S. V. Deroover L. Preston T. Vermeulen K. Preter V. D. (2017 ). Systemic availability and metabolism of colonic-derived short-chain fatty acids in healthy subjects: A stable isotope study. J. Physiol. 595 541–555.

    Not in our library10.1113/jp272613

  13. 13.

    Bowe W. Patel N. B. Logan A. C. (2014 ). Acne vulgaris, probiotics and the gut-brain-skin axis: From anecdote to translational medicine. Benef. Microbes 5 185–199.

    Not in our library10.3920/bm2012.0060

  14. 14.

    Canfora E. E. Jocken J. W. Blaak E. E. (2015 ). Short-chain fatty acids in control of body weight and insulin sensitivity. Nat. Rev. Endocrinol. 11 577–591.

    Not in our library10.1038/nrendo.2015.128

  15. 15.

    Carrion S. L. Sutter C. H. Sutter T. R. (2014 ). Combined treatment with sodium butyrate and PD153035 enhances keratinocyte differentiation. Exp. Dermatol. 23 211–214.

    Not in our library10.1111/exd.12333

  16. 16.

    Chen Y. E. Fischbach M. A. Belkaid Y. (2018 ). Skin microbiota-host interactions. Nature 553 427–436.

    Not in our library10.1038/nature25177

  17. 17.

    Cheng H. Y. Chan J. C. Y. Yap G. C. Huang C.-H. Kioh D. Y. Q. Tham E. H. (2022 ). Evaluation of stool short chain fatty acids profiles in the first year of life with childhood atopy-related outcomes. Front. Allergy 3:873168.

    Not in our library10.3389/falgy.2022.873168

  18. 18.

    Chun J. Lee S. M. Ahn Y. M. Baek M.-G. Yi H. Shin S. (2021 ). Modulation of the gut microbiota by sihocheonggan-tang shapes the immune responses of atopic dermatitis. Front. Pharmacol. 12:722730.

    Not in our library10.3389/fphar.2021.722730

  19. 19.

    Cleophas M. C. P. Crişan T. O. Lemmers H. Toenhake-Dijkstra H. Fossati G. Jansen T. L. (2016 ). Suppression of monosodium urate crystal-induced cytokine production by butyrate is mediated by the inhibition of class I histone deacetylases. Ann. Rheum. Dis. 75 593–600.

    Not in our library10.1136/annrheumdis-2014-206258

  20. 20.

    Coppola S. Avagliano C. Sacchi A. Laneri S. Calignano A. Voto L. (2022 ). Potential clinical applications of the postbiotic butyrate in human skin diseases. Molecules 27:1849.

    Not in our library10.3390/molecules27061849

  21. 21.

    Cummings J. H. Pomare E. W. Branch W. J. Naylor C. P. Macfarlane G. T. (1987 ). Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 28 1221–1227.

    Not in our library10.1136/gut.28.10.1221

  22. 22.

    Deng F. Zhang L.-Q. Wu H. Chen Y. Yu W.-Q. Han R.-H. (2022 ). Propionate alleviates myocardial ischemia-reperfusion injury aggravated by angiotensin II dependent on caveolin-1/ACE2 axis through GPR41. Int. J. Biol. Sci. 18 858–872.

    Not in our library10.7150/ijbs.67724

  23. 23.

    Diakos C. Prieschl E. E. Säemann M. D. Böhmig G. A. Csonga R. Sobanov Y. (2006 ). N-Butyrate inhibits Jun NH(2)-terminal kinase activation and cytokine transcription in mast cells. Biochem. Biophys. Res. Commun. 349 863–868.

    Not in our library10.1016/j.bbrc.2006.08.117

  24. 24.

    Diotallevi F. Campanati A. Martina E. Radi G. Paolinelli M. Marani A. (2022 ). The role of nutrition in immune-mediated, inflammatory skin disease: A narrative review. Nutrients 14:591.

    Not in our library10.3390/nu14030591

  25. 25.

    Eisenstein M. (2020 ). The skin microbiome. Nature 588:S209.

    Not in our library10.1038/d41586-020-03523-7

  26. 26.

    Elias P. M. Steinhoff M. (2008 ). “Outside-to-inside” (and now back to “outside”) pathogenic mechanisms in atopic dermatitis. J. Invest. Dermatol. 128 1067–1070.

    Not in our library10.1038/jid.2008.88

  27. 27.

    Eslick S. Williams E. J. Berthon B. S. Wright T. Karihaloo C. Gately M. (2022 ). Weight loss and short-chain fatty acids reduce systemic inflammation in monocytes and adipose tissue macrophages from obese subjects. Nutrients 14:765.

    Not in our library10.3390/nu14040765

  28. 28.

    Fang Z. Li L. Zhao J. Zhang H. Lee Y.-K. Lu W. (2020 ). Bifidobacteria adolescentis regulated immune responses and gut microbial composition to alleviate DNFB-induced atopic dermatitis in mice. Eur. J. Nutr. 59 3069–3081.

    Not in our library10.1007/s00394-019-02145-8

  29. 29.

    Folkerts J. Redegeld F. Folkerts G. Blokhuis B. Berg M. P. M. V. D. Bruijn M. J. W. D. (2020 ). Butyrate inhibits human mast cell activation via epigenetic regulation of FcεRI-mediated signaling. Allergy 75 1966–1978.

    Not in our library10.1111/all.14254

  30. 30.

    Fraise A. P. Wilkinson M. A. C. Bradley C. R. Oppenheim B. Moiemen N. (2013 ). The antibacterial activity and stability of acetic acid. J. Hosp. Infect. 84 329–331.

    Not in our library10.1016/j.jhin.2013.05.001

  31. 31.

    Freedberg I. M. Tomic-Canic M. Komine M. Blumenberg M. (2001 ). Keratins and the keratinocyte activation cycle. J. Invest. Dermatol. 116 633–640.

    Not in our library10.1046/j.1523-1747.2001.01327.x

  32. 32.

    Furue K. Ito T. Furue M. (2018 ). Differential efficacy of biologic treatments targeting the TNF-α/IL-23/IL-17 axis in psoriasis and psoriatic arthritis. Cytokine 111 182–188.

    Not in our library10.1016/j.cyto.2018.08.025

  33. 33.

    Galli S. J. Dvorak A. M. Marcum J. A. Ishizaka T. Nabel G. Simonian H. D. (1982 ). Mast cell clones: A model for the analysis of cellular maturation. J. Cell Biol. 95(2 Pt 1) 435–444.

    Not in our library10.1083/jcb.95.2.435

  34. 34.

    Gio-Batta M. Sjöberg F. Jonsson K. Barman M. Lundell A.-C. Adlerberth I. (2020 ). Fecal short chain fatty acids in children living on farms and a link between valeric acid and protection from eczema. Sci. Rep. 10:22449.

    Not in our library10.1038/s41598-020-79737-6

  35. 35.

    Haase S. Haghikia A. Wilck N. Müller D. N. Linker R. A. (2018 ). Impacts of microbiome metabolites on immune regulation and autoimmunity. Immunology 154 230–238.

    Not in our library10.1111/imm.12933

  36. 36.

    Hee B. V. D. Wells J. M. (2021 ). Microbial regulation of host physiology by short-chain fatty acids. Trends Microbiol. 29 700–712.

    Not in our library10.1016/j.tim.2021.02.001

  37. 37.

    Hu Y.-Q. Liu P. Mu Z.-L. Zhang J.-Z. (2020 ). Aryl hydrocarbon receptor expression in serum, peripheral blood mononuclear cells, and skin lesions of patients with atopic dermatitis and its correlation with disease severity. Chin. Med. J. 133 148–153.

    Not in our library10.1097/cm9.0000000000000591

  38. 38.

    Ismail I. H. Oppedisano F. Joseph S. J. Boyle R. J. Licciardi P. V. Robins-Browne R. M. (2012 ). Reduced gut microbial diversity in early life is associated with later development of eczema but not atopy in high-risk infants. Pediatr. Allergy Immunol. 23 674–681.

    Not in our library10.1111/j.1399-3038.2012.01328.x

  39. 39.

    Isobe J. Maeda S. Obata Y. Iizuka K. Nakamura Y. Fujimura Y. (2020 ). Commensal-bacteria-derived butyrate promotes the T-cell-independent IgA response in the colon. Int. Immunol. 32 243–258.

    Not in our library10.1093/intimm/dxz078

  40. 40.

    Iwase T. Uehara Y. Shinji H. Tajima A. Seo H. Takada K. (2010 ). Staphylococcus epidermidis Esp inhibits Staphylococcus aureus biofilm formation and nasal colonization. Nature 465 346–349.

    Not in our library10.1038/nature09074

  41. 41.

    Jiménez M. Muñoz F. C. Cervantes-García D. Cervantes M. M. Hernández-Mercado A. Barrón-García B. (2020 ). Protective effect of glycomacropeptide on the atopic dermatitis-like dysfunctional skin barrier in rats. J. Med. Food 23 1216–1224.

    Not in our library10.1089/jmf.2019.0247

  42. 42.

    Kaesler S. Volz T. Skabytska Y. Köberle M. Hein U. Chen K.-M. (2014 ). Toll-like receptor 2 ligands promote chronic atopic dermatitis through IL-4–mediated suppression of IL-10. J. Allergy Clin. Immunol. 134 92–99.

    Not in our library10.1016/j.jaci.2014.02.017

  43. 43.
    Butyrate Conditions Human Dendritic Cells to Prime Type 1 Regulatory T Cells via both Histone Deacetylase Inhibition and G Protein-Coupled Receptor 109A Signaling · 2017
    No notice
  44. 44.

    Kalb B. Marenholz I. Jeanrenaud A. C. S. N. Meixner L. Arnau-Soler A. Rosillo-Salazar O. D. (2022 ). Filaggrin loss-of-function mutations are associated with persistence of egg and milk allergy. J. Allergy Clin. Immunol. 150 1125–1134.

    Not in our library10.1016/j.jaci.2022.05.018

  45. 45.

    Kanda N. Hoashi T. Saeki H. (2021 ). The defect in regulatory T cells in psoriasis and therapeutic approaches. J. Clin. Med. 10:3880.

    Not in our library10.3390/jcm10173880

  46. 46.

    Kang H. J. Kim G.-C. Lee C.-G. Park S. Sharma G. Verma R. (2021 ). Probiotics-derived metabolite ameliorates skin allergy by promoting differentiation of FOXP3(+) regulatory T cells. J. Allergy Clin. Immunol. 147 1517–1521.

    Not in our library10.1016/j.jaci.2020.11.040

  47. 47.

    Kang M. J. Lee S. Y. Park Y. M. Kim B. S. Lee M. J. Kim J. H. (2021 ). Interactions between IL-17 variants and Streptococcus in the gut contribute to the development of atopic dermatitis in infancy. Allergy Asthma Immunol. Res. 13 404–419.

    Not in our library10.4168/aair.2021.13.3.404

  48. 48.

    Kao M. S. Huang S. Chang W. L. Hsieh M. F. Huang C. J. Gallo R. L. (2017 ). Microbiome precision editing: Using PEG as a selective fermentation initiator against methicillin-resistant Staphylococcus aureus. Biotechnol. J. 12 1–20.

    Not in our library10.1002/biot.201600399

  49. 49.

    Karaki S.-I. Mitsui R. Hayashi H. Kato I. Sugiya H. Iwanaga T. (2006 ). Short-chain fatty acid receptor, GPR43, is expressed by enteroendocrine cells and mucosal mast cells in rat intestine. Cell Tissue Res. 324 353–360.

    Not in our library10.1007/s00441-005-0140-x

  50. 50.

    Karamani C. Antoniadou I. T. Dimou A. Andreou E. Kostakis G. Sideri A. (2021 ). Optimization of psoriasis mouse models. J. Pharmacol. Toxicol. Methods 108:107054.

    Not in our library10.1016/j.vascn.2021.107054

  51. 51.

    Khyshiktuev B. S. Karavaeva T. M. Fal’ko E. V. (2008 ). Variability of quantitative changes in short-chain fatty acids in serum and epidermis in psoriasis. Klin. Lab. Diagn. 8:22.

    Not in our library

  52. 52.

    Kim C. H. Kim J. Y. Lee A. Y. (2015 ). Therapeutic and immunomodulatory effects of glucosamine in combination with low-dose cyclosporine A in a murine model of imiquimod-induced psoriasis. Eur. J. Pharmacol. 756 43–51.

    Not in our library10.1016/j.ejphar.2015.03.010

  53. 53.

    Kim H. J. Lee S. H. Hong S. J. (2020 ). Antibiotics-induced dysbiosis of intestinal microbiota aggravates atopic dermatitis in mice by altered short-chain fatty acids. Allergy Asthma Immunol. Res. 12 137–148.

    Not in our library10.4168/aair.2020.12.1.137

  54. 54.

    Kim H. K. Rutten N. B. M. M. Vaart I. B.-V. D. Niers L. E. M. Choi Y. H. Rijkers G. T. (2015 ). Probiotic supplementation influences faecal short chain fatty acids in infants at high risk for eczema. Benef. Microbes 6 783–790.

    Not in our library10.3920/bm2015.0056

  55. 55.

    Kim H. O. Kim J. H. Chung B. Y. Choi M. G. Park C. W. (2014 ). Increased expression of the aryl hydrocarbon receptor in patients with chronic inflammatory skin diseases. Exp. Dermatol. 23 278–281.

    Not in our library10.1111/exd.12350

  56. 56.

    Kim J.-H. Kim K. Kim W. (2019 ). Cream cheese-derived Lactococcus chungangensis CAU 28 modulates the gut microbiota and alleviates atopic dermatitis in BALB/c Mice. Sci. Rep. 9:446.

    Not in our library10.1038/s41598-018-36864-5

  57. 57.

    Kleuskens M. T. A. Haasnoot M. L. Herpers B. M. Ampting M. T. J. V. Bredenoord A. J. Garssen J. (2022 ). Butyrate and propionate restore interleukin 13-compromised esophageal epithelial barrier function. Allergy 77 1510–1521.

    Not in our library10.1111/all.15069

  58. 58.

    Koh A. Vadder F. D. Kovatcheva-Datchary P. Bäckhed F. (2016 ). From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites. Cell 165 1332–1345.

    Not in our library10.1016/j.cell.2016.05.041

  59. 59.

    Kong H. H. Segre J. A. (2012 ). Skin microbiome: Looking back to move forward. J. Invest. Dermatol. 132(3 Pt 2) 933–939.

    Not in our library10.1038/jid.2011.417

  60. 60.

    Korsten S. G. P. J. Peracic L. Groeningen L. M. B. V. Diks M. A. P. Vromans H. Garssen J. (2022 ). Butyrate prevents induction of CXCL10 and non-canonical IRF9 expression by activated human intestinal epithelial cells via HDAC inhibition. Int. J. Mol. Sci. 23:3980.

    Not in our library10.3390/ijms23073980

  61. 61.

    Krejner A. Bruhs A. Mrowietz U. Wehkamp U. Schwarz T. Schwarz A. (2018 ). Decreased expression of G-protein-coupled receptors GPR43 and GPR109a in psoriatic skin can be restored by topical application of sodium butyrate. Arch. Dermatol. Res. 310 751–758.

    Not in our library10.1007/s00403-018-1865-1

  62. 62.

    Lee Y. I. Lee S. G. Kim J. Choi S. Jung I. Lee J. H. (2021 ). Proteoglycan combined with hyaluronic acid and hydrolyzed collagen restores the skin barrier in mild atopic dermatitis and dry, eczema-prone skin: A pilot study. Int. J. Mol. Sci. 22:10189.

    Not in our library10.3390/ijms221910189

  63. 63.

    Leung D. Y. M. (2013 ). New insights into atopic dermatitis: Role of skin barrier and immune dysregulation. Allergol. Int. 62 151–161.

    Not in our library10.2332/allergolint.13-rai-0564

  64. 64.

    Li Y. Dong J. Xiao H. Zhang S. Wang B. Cui M. (2020 ). Gut commensal derived-valeric acid protects against radiation injuries. Gut Microbes 11 789–806.

    Not in our library10.1080/19490976.2019.1709387

  65. 65.

    Lin X. Meng X. Song Z. Lin J. (2022 ). Peroxisome proliferator-activator receptor γ and psoriasis, molecular and cellular biochemistry. Mol. Cell Biochem. 477 1905–1920.

    Not in our library10.1007/s11010-022-04417-0

  66. 66.

    Lu W. Deng Y. Fang Z. Zhai Q. Cui S. Zhao J. (2021 ). Potential role of probiotics in ameliorating psoriasis by modulating gut microbiota in imiquimod-induced psoriasis-like mice. Nutrients 13:2010.

    Not in our library10.3390/nu13062010

  67. 67.

    Luu L. A. Flowers R. H. Gao Y. Wu M. Gasperino S. Kellams A. L. (2021 ). Apple cider vinegar soaks do not alter the skin bacterial microbiome in atopic dermatitis. PLoS One 16:e0252272.

    Not in our library10.1371/journal.pone.0252272

  68. 68.
    The short-chain fatty acid pentanoate suppresses autoimmunity by modulating the metabolic-epigenetic crosstalk in lymphocytes · 2019
    No notice
  69. 69.

    Mao J. W. Tang H. Y. Wang Y. D. (2012 ). Influence of rosiglitazone on the expression of PPARγ, NF-κB, and TNF-α in rat model of ulcerative colitis. Gastroenterol. Res. Pract. 2012:845672.

    Not in our library10.1155/2012/845672

  70. 70.

    Marinissen M. J. Gutkind J. S. (2001 ). G-protein-coupled receptors and signaling networks: Emerging paradigms. Trends Pharmacol. Sci. 22 368–376.

    Not in our library10.1016/s0165-6147(00)01678-3

  71. 71.
    Butyrate produced by gut commensal bacteria activates TGF-beta1 expression through the transcription factor SP1 in human intestinal epithelial cells · 2018
    No notice
  72. 72.

    Maslowski K. M. Vieira A. T. Ng A. Kranich J. Sierro F. Yu D. (2009 ). Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461 1282–1286.

    Not in our library10.1038/nature08530

  73. 73.

    Meijer K. Vos P. D. Priebe M. G. (2010 ). Butyrate and other short-chain fatty acids as modulators of immunity: What relevance for health? Curr. Opin. Clin. Nutr. Metab. Care 13 715–721.

    Not in our library10.1097/mco.0b013e32833eebe5

  74. 74.

    Nadeem A. Ahmad S. F. Al-Harbi N. O. El-Sherbeeny A. M. Al-Harbi M. M. Almukhlafi T. S. (2017 ). GPR43 activation enhances psoriasis-like inflammation through epidermal upregulation of IL-6 and dual oxidase 2 signaling in a murine model. Cell. Signal. 33 59–68.

    Not in our library10.1016/j.cellsig.2017.02.014

  75. 75.

    Naik S. Bouladoux N. Wilhelm C. Molloy M. J. Salcedo R. Kastenmuller W. (2012 ). Compartmentalized control of skin immunity by resident commensals. Science 337 1115–1119.

    Not in our library10.1126/science.1225152

  76. 76.

    Narla S. Silverberg J. I. (2020 ). Multimorbidity and mortality risk in hospitalized adults with chronic inflammatory skin disease in the United States. Arch. Dermatol. Res. 312 507–512.

    Not in our library10.1007/s00403-020-02043-8

  77. 77.

    Nguyen T. D. Hållenius F. F. Lin X. Nyman M. Prykhodko O. (2020 ). Monobutyrin and monovalerin affect brain short-chain fatty acid profiles and tight-junction protein expression in ApoE-knockout rats fed high-fat diets. Nutrients 12:1202.

    Not in our library10.3390/nu12041202

  78. 78.

    Nylund L. Nermes M. Isolauri E. Salminen S. Vos W. M. D. Satokari R. (2015 ). Severity of atopic disease inversely correlates with intestinal microbiota diversity and butyrate-producing bacteria. Allergy 70 241–244.

    Not in our library10.1111/all.12549

  79. 79.

    Ohira H. Tsutsui W. Fujioka Y. (2017 ). Are short chain fatty acids in gut microbiota defensive players for inflammation and atherosclerosis? J. Atheroscler. Thromb. 24 660–672.

    Not in our library10.5551/jat.rv17006

  80. 80.

    O’Neill C. A. Monteleone G. McLaughlin J. T. Paus R. (2016 ). The gut-skin axis in health and disease: A paradigm with therapeutic implications. Bioessays 38 1167–1176.

    Not in our library10.1002/bies.201600008

  81. 81.

    Park J. S. Lee E. J. Lee J. C. Kim W. K. Kim H. S. (2007 ). Anti-inflammatory effects of short chain fatty acids in IFN-gamma-stimulated RAW 264.7 murine macrophage cells: Involvement of NF-kappaB and ERK signaling pathways. Int. Immunopharmacol. 7 70–77.

    Not in our library10.1016/j.intimp.2006.08.015

  82. 82.

    Park Y. M. Lee S. Y. Kang M. J. Kim B. S. Lee M. J. Jung S. S. (2020 ). Imbalance of Gut Streptococcus, Clostridium, and Akkermansia determines the natural course of atopic dermatitis in infant. Allergy Asthma Immunol. Res. 12 322–337.

    Not in our library10.4168/aair.2020.12.2.322

  83. 83.

    Peng S. Zhang T. Zhang S. Tang Q. Yan Y. Feng H. (2022 ). Integrated bioinformatics and validation reveal IL1B and Its related molecules as potential biomarkers in chronic spontaneous urticaria. Front. Immunol. 13:850993.

    Not in our library10.3389/fimmu.2022.850993

  84. 84.

    Perdijk O. Baarlen P. V. Fernandez-Gutierrez M. M. Brink E. V. D. Schuren F. H. J. Brugman S. (2019 ). Sialyllactose and galactooligosaccharides promote epithelial barrier functioning and distinctly modulate microbiota composition and short chain fatty acid production in vitro. Front. Immunol. 10:94.

    Not in our library10.3389/fimmu.2019.00094

  85. 85.
    Gut–Skin Axis: Current Knowledge of the Interrelationship between Microbial Dysbiosis and Skin Conditions · 2021
    No notice
  86. 86.
    The Extracellular Matrix in Skin Inflammation and Infection · 2021
    No notice
  87. 87.

    Rauf A. Khalil A. A. Rahman U.-U. Khalid A. Naz S. Shariati M. A. (2022 ). Recent advances in the therapeutic application of short-chain fatty acids (SCFAs): An updated review. Crit. Rev. Food Sci. Nutr. 62 6034–6054.

    Not in our library10.1080/10408398.2021.1895064

  88. 88.
    Gut microbiota profile in children affected by atopic dermatitis and evaluation of intestinal persistence of a probiotic mixture · 2019
    No notice
  89. 89.

    Ren T. Glatt D. U. Nguyen T. N. Allen E. K. Early S. V. Sale M. (2013 ). 16S rRNA survey revealed complex bacterial communities and evidence of bacterial interference on human adenoids. Environ. Microbiol. 15 535–547.

    Not in our library10.1111/1462-2920.12000

  90. 90.
    Psoriasis Pathogenesis and Treatment · 2019
    No notice
  91. 91.
    Intestinal Short Chain Fatty Acids and their Link with Diet and Human Health · 2016
    No notice
  92. 92.

    Rodriguez R. S. Pauli M. L. Neuhaus I. M. Yu S. S. Arron S. T. Harris H. W. (2014 ). Memory regulatory T cells reside in human skin. J. Clin. Invest. 124 1027–1036.

    Not in our library10.1172/jci72932

  93. 93.

    Roduit C. Frei R. Ferstl R. Loeliger S. Westermann P. Rhyner C. (2019 ). High levels of butyrate and propionate in early life are associated with protection against atopy. Allergy 74 799–809.

    Not in our library10.1111/all.13660

  94. 94.
    Microbiota-Derived Metabolites Suppress Arthritis by Amplifying Aryl-Hydrocarbon Receptor Activation in Regulatory B Cells · 2020
    No notice
  95. 95.

    Roth W. Kumar V. Beer H.-D. Richter M. Wohlenberg C. Reuter U. (2012 ). Keratin 1 maintains skin integrity and participates in an inflammatory network in skin through interleukin-18. J. Cell Sci. 125(Pt 22) 5269–5279.

    Not in our library10.1242/jcs.116574

  96. 96.

    Sandin A. Bråbäck L. Norin E. Björkstén B. (2009 ). Faecal short chain fatty acid pattern and allergy in early childhood. Acta Paediatr. 98 823–827.

    Not in our library10.1111/j.1651-2227.2008.01215.x

  97. 97.

    Sanford J. A. Zhang L.-J. Williams M. R. Gangoiti J. A. Huang C.-M. Gallo R. L. (2016 ). Inhibition of HDAC8 and HDAC9 by microbial short-chain fatty acids breaks immune tolerance of the epidermis to TLR ligands. Sci. Immunol. 1:eaah4609.

    Not in our library10.1126/sciimmunol.aah4609

  98. 98.

    Scanlan P. D. Buckling A. Kong W. Wild Y. Lynch S. V. Harrison F. (2012 ). Gut dysbiosis in cystic fibrosis. J. Cyst. Fibros. 11 454–455.

    Not in our library10.1016/j.jcf.2012.03.007

  99. 99.

    Schauber J. Dorschner R. A. Yamasaki K. Brouha B. Gallo R. L. (2006 ). Control of the innate epithelial antimicrobial response is cell-type specific and dependent on relevant microenvironmental stimuli. Immunology 118 509–519.

    Not in our library10.1111/j.1365-2567.2006.02399.x

  100. 100.

    Schauber J. Oda Y. Büchau A. S. Yun Q.-C. Steinmeyer A. Zügel U. (2008 ). Histone acetylation in keratinocytes enables control of the expression of cathelicidin and CD14 by 1,25-dihydroxyvitamin D3. J. Invest. Dermatol. 128 816–824.

    Not in our library10.1038/sj.jid.5701102

  101. 101.

    Schilf P. Künstner A. Olbrich M. Waschina S. Fuchs B. Galuska C. E. (2021 ). A mitochondrial polymorphism alters immune cell metabolism and protects mice from skin inflammation. Int. J. Mol. Sci. 22:1006.

    Not in our library10.3390/ijms22031006

  102. 102.
    Short-Chain Fatty Acid and FFAR2 Activation – A New Option for Treating Infections? · 2021
    Not checked
  103. 103.

    Schwarz A. Bruhs A. Schwarz T. (2017 ). The short-chain fatty acid sodium butyrate functions as a regulator of the skin immune system. J. Invest. Dermatol. 137 855–864.

    Not in our library10.1016/j.jid.2016.11.014

  104. 104.

    Schwarz A. Philippsen R. Schwarz T. (2021 ). Induction of regulatory T cells and correction of cytokine disbalance by short-chain fatty acids: Implications for psoriasis therapy. J. Invest. Dermatol. 141 95–104.

    Not in our library10.1016/j.jid.2020.04.031

  105. 105.

    Simon D. Aeberhard C. Erdemoglu Y. Simon H.-U. (2014 ). Th17 cells and tissue remodeling in atopic and contact dermatitis. Allergy 69 125–131.

    Not in our library10.1111/all.12351

  106. 106.

    Sina C. Gavrilova O. Förster M. Till A. Derer S. Hildebrand F. (2009 ). G protein-coupled receptor 43 is essential for neutrophil recruitment during intestinal inflammation. J. Immunol. 183 7514–7522.

    Not in our library10.4049/jimmunol.0900063

  107. 107.

    Singh N. Gurav A. Sivaprakasam S. Brady E. Padia R. Shi H. (2014 ). Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 40 128–139.

    Not in our library10.1016/j.immuni.2013.12.007

  108. 108.

    Smith P. M. Howitt M. R. Panikov N. Michaud M. Gallini C. A. Bohlooly-Y M. (2013 ). The microbial metabolites. short-chain fatty acids, regulate colonic treg cell homeostasis. Science 341 569–573.

    Not in our library10.1126/science.1241165

  109. 109.

    Song H. Yoo Y. Hwang J. Na Y.-C. Kim H. S. (2016 ). Faecalibacterium prausnitzii subspecies–level dysbiosis in the human gut microbiome underlying atopic dermatitis. J. Allergy Clin. Immunol. 137 852–860.

    Not in our library10.1016/j.jaci.2015.08.021

  110. 110.

    Stockenhuber K. Hegazy A. N. West N. R. Ilott N. E. Stockenhuber A. Bullers S. J. (2018 ). Foxp3(+) T reg cells control psoriasiform inflammation by restraining an IFN-I-driven CD8(+) T cell response. J. Exp. Med. 215 1987–1998.

    Not in our library10.1084/jem.20172094

  111. 111.

    Sugiyama H. Nonaka T. Kishimoto T. Komoriya K. Tsuji K. Nakahata T. (2000 ). Peroxisome proliferator-activated receptors are expressed in mouse bone marrow-derived mast cells. Jpn. J. Pharmacol. 82 259–262.

    Not in our library10.1016/s0014-5793(00)01169-8

  112. 112.

    Sunkara L. T. Jiang W. Zhang G. (2012 ). Modulation of antimicrobial host defense peptide gene expression by free fatty acids. PLoS One 7:e49558.

    Not in our library10.1371/journal.pone.0049558

  113. 113.

    Ta L. D. H. Chan J. C. Y. Yap G. C. Purbojati R. W. Drautz-Moses D. I. Koh Y. M. (2020 ). A compromised developmental trajectory of the infant gut microbiome and metabolome in atopic eczema. Gut Microbes 12 1–22.

    Not in our library10.1080/19490976.2020.1801964

  114. 114.

    Tachibana M. Wada K. Katayama K. Kamisaki Y. Maeyama K. Kadowaki T. (2008 ). Activation of peroxisome proliferator-activated receptor gamma suppresses mast cell maturation involved in allergic diseases. Allergy 63 1136–1147.

    Not in our library10.1111/j.1398-9995.2008.01677.x

  115. 115.

    Takeshita J. Grewal S. Langan S. M. Mehta N. N. Ogdie A. Voorhees A. S. V. (2017 ). Psoriasis and comorbid diseases epidemiology. J. Am. Acad. Dermatol. 76 377–390.

    Not in our library10.1016/j.jaad.2016.07.064

  116. 116.

    Tan J. McKenzie C. Potamitis M. Thorburn A. N. Mackay C. R. Macia L. (2014 ). The role of short-chain fatty acids in health and disease. Adv. Immunol. 121 91–119.

    Not in our library10.1016/b978-0-12-800100-4.00003-9

  117. 117.

    Thiruvengadam M. Subramanian U. Venkidasamy B. Thirupathi P. Samynathan R. Shariati M. A. (2021 ). Emerging role of nutritional short-chain fatty acids (SCFAs) against cancer via modulation of hematopoiesis. Crit. Rev. Food Sci. Nutr. 1–18.

    Not in our library10.1080/10408398.2021.1954874

  118. 118.

    Traisaeng S. Herr D. R. Kao H.-J. Chuang T.-H. Huang C.-M. (2019 ). A derivative of butyric acid, the fermentation metabolite of Staphylococcus epidermidis, inhibits the growth of a Staphylococcus aureus strain isolated from atopic dermatitis patients. Toxins 11:311.

    Not in our library10.3390/toxins11060311

  119. 119.

    Trompette A. Gollwitzer E. S. Pattaroni C. Lopez-Mejia I. C. Riva E. Pernot J. (2018 ). Dietary fiber confers protection against Flu by shaping Ly6c(-) patrolling monocyte hematopoiesis and CD8(+) T cell metabolism. Immunity 48 992.e8–1005.e8.

    Not in our library10.1016/j.immuni.2018.04.022

  120. 120.

    Trompette A. Gollwitzer E. S. Yadava K. Sichelstiel A. K. Sprenger N. Ngom-Bru C. (2014 ). Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat. Med. 20 159–166.

    Not in our library10.1038/nm.3444

  121. 121.
    Gut-derived short-chain fatty acids modulate skin barrier integrity by promoting keratinocyte metabolism and differentiation · 2022
    No notice
  122. 122.

    Victora C. G. Bahl R. Barros A. J. D. França G. V. A. Horton S. Krasevec J. (2016 ). Breastfeeding in the 21st century: Epidemiology, mechanisms, and lifelong effect. Lancet 387 475–490.

    Not in our library10.1016/s0140-6736(15)01024-7

  123. 123.

    Vonk R. J. Reckman G. (2017 ). Progress in the biology and analysis of short chain fatty acids. J. Physiol. 595 419–420.

    Not in our library10.1113/jp273260

  124. 124.

    Wang C. C. Wu H. Lin F. H. Gong R. Xie F. Peng Y. (2018 ). Sodium butyrate enhances intestinal integrity, inhibits mast cell activation, inflammatory mediator production and JNK signaling pathway in weaned pigs. Innate Immun. 24 40–46.

    Not in our library10.1177/1753425917741970

  125. 125.

    Wang D. Guo S. He H. Gong L. Cui H. (2020 ). Gut microbiome and serum metabolome analyses identify unsaturated fatty acids and butanoate metabolism induced by gut microbiota in patients with chronic spontaneous urticaria. Front. Cell. Infect. Microbiol. 10:24.

    Not in our library10.3389/fcimb.2020.00024

  126. 126.

    Wang M. Karlsson C. Olsson C. Adlerberth I. Wold A. E. Strachan D. P. (2007 ). Reduced diversity in the early fecal microbiota of infants with atopic eczema. J. Allergy Clin. Immunol. 121 129–134.

    Not in our library10.1016/j.jaci.2007.09.011

  127. 127.

    Wang X. Yi W. He L. Luo S. Wang J. Jiang L. (2021 ). Abnormalities in gut microbiota and metabolism in patients with chronic spontaneous urticaria. Front. Immunol. 12:691304.

    Not in our library10.3389/fimmu.2021.691304

  128. 128.

    Wang Y. Kao M.-S. Yu J. Huang S. Marito S. Gallo R. L. (2016 ). A precision microbiome approach using sucrose for selective augmentation of Staphylococcus epidermidis fermentation against Propionibacterium acnes. Int. J. Mol. Sci. 17:1870.

    Not in our library10.3390/ijms17111870

  129. 129.

    Wei Z. Xiao C. Guo C. Zhang X. Wang Y. Wang J. (2017 ). Sodium acetate inhibits Staphylococcus aureus internalization into bovine mammary epithelial cells by inhibiting NF-κB activation. Microb. Pathog. 107 116–121.

    Not in our library10.1016/j.micpath.2017.03.030

  130. 130.

    Williams H. Flohr C. (2006 ). How epidemiology has challenged 3 prevailing concepts about atopic dermatitis. J. Allergy Clin. Immunol. 118 209–213.

    Not in our library10.1016/j.jaci.2006.04.043

  131. 131.

    Wong J. M. W. Souza R. D. Kendall C. W. C. Emam A. Jenkins D. J. A. (2006 ). Colonic health: Fermentation and short chain fatty acids. J. Clin. Gastroenterol. 40 235–243.

    Not in our library10.1097/00004836-200603000-00015

  132. 132.

    Wopereis H. Sim K. Shaw A. Warner J. O. Knol J. Kroll J. S. (2018 ). Intestinal microbiota in infants at high risk for allergy: Effects of prebiotics and role in eczema development. J. Allergy Clin. Immunol. 141 1334–1342.

    Not in our library10.1016/j.jaci.2017.05.054

  133. 133.

    Wu J. Guo R. Chai J. Xiong W. Tian M. Lu W. (2021 ). The protective effects of Cath-MH with anti-Propionibacterium acnes and anti-inflammation functions on acne vulgaris. Front. Pharmacol. 12:788358.

    Not in our library10.3389/fphar.2021.788358

  134. 134.
    Health Benefits and Side Effects of Short-Chain Fatty Acids · 2022
    No notice
  135. 135.

    Yao Y. Cai X. Fei W. Ye Y. Zhao M. Zheng C. (2022 ). The role of short-chain fatty acids in immunity, inflammation and metabolism. Crit. Rev. Food Sci. Nutr. 62 1–12.

    Not in our library10.1080/10408398.2020.1854675

  136. 136.
    Human gut bacteria as potent class I histone deacetylase inhibitors in vitro through production of butyric acid and valeric acid · 2018
    No notice
  137. 137.

    Zanten G. C. V. Knudsen A. Röytiö H. Forssten S. Lawther M. Blennow A. (2012 ). The effect of selected synbiotics on microbial composition and short-chain fatty acid production in a model system of the human colon. PLoS One 7:e47212.

    Not in our library10.1371/journal.pone.0047212

  138. 138.
    Ferulic acid mediates prebiotic responses of cereal-derived arabinoxylans on host health · 2022
    Not checked
  139. 139.

    Zuberbier T. Latiff A. H. A. Abuzakouk M. Aquilina S. Asero R. Baker D. (2021 ). The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis and management of urticaria. Allergy 77 734–766.

    Not in our library10.1111/all.15090

Cited by papers we hold 1

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.